Breakthrough Targeted Therapy Shows Promise for KRAS-Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role
FOR IMMEDIATE RELEASE Breakthrough Targeted Therapy Shows Promise for KRAS-Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role Fairfax, VA — May 12, 2026 — Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first-in-class targeted oral therapy for patients […]
Dr. Danijela Jelovac and Dr. Lindy Rosal Spotlighted in Washingtonian for Advancing Breast Cancer Treatment
Congratulations to our physicians, Dr. Danijela Jelovac and Dr. Lindy Rosal, for being featured in the October 2025 issue of Washingtonian magazine in honor of Breast Cancer Awareness Month. The article, “Hope through Innovation,” highlights the cutting-edge work being done at Virginia Cancer Specialists in the areas of targeted therapies, advanced surgical techniques, and personalized […]
Improved Survival with a Chemotherapy Free Option for EGFR Mutated Lung Cancer
Living with advanced non–small cell lung cancer (NSCLC) driven by mutations in the EGFR gene can feel overwhelming. For many patients, treatment has meant targeted therapy with the gold standard osimertinib, an oral targeted therapy directed toward the EGFR mutated tumor cells. Data from the large MARIPOSA trial published in September 2025 in The New […]
New Treatment Breakthrough: Amivantamab Plus Lazertinib for Advanced Lung Cancer – Timothy A. McCarthy, MD
A groundbreaking study published in June 2024 in The New England Journal of Medicine has introduced a promising new treatment for a specific type of advanced lung cancer. The research, co-authored by Alex Spira, MD, PhD, FACP, FACSO, Medical Oncologist and Co-Director of The Virginia Cancer Specialists Research Institute, highlights the combination of two drugs, […]
A New Era in Bladder Cancer Treatment: Targeted Therapy Offers Hope – Daniel Chong, MD, Virginia Cancer Specialists
Bladder cancer, though not as widely discussed as some other cancers, is a significant health concern worldwide. With approximately 82,000 new cases each year, and sadly, 16,700 annual deaths attributed to it, it demands attention and innovative solutions. Fortunately, advancements in medical science have led to a greater understanding of bladder cancer and improved […]
Investigational Inhibitor of Active RAS Shows Clinical Promise – Alexander I. Spira, MD, PhD, FACP
Investigational Inhibitor of Active RAS Shows Clinical Promise – The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C
Landmark Non-Small Cell Lung Cancer Study – Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP
Virginia Cancer Specialists Research Institute – Landmark “Non-Small Cell Lung Cancer Study” – Alexander I. Spira, MD, PhD, FACP Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib – See the […]